Abstract: AIM: To investigate the effect of Dengzhan Shengmai capsules on the secondary prevention of atherosclerotic cerebral infarction. METHODS: 110 patients with cerebral infarction from June 2009 to June 2012 in the hospital were randomly divided into observation group and control group. Conducting the secondary prevention treatment measures, the control group was treated with atorvastatin (10 mg, Qn) and aspirin enteric-coated tablets(100 mg, q.d.). The observation group was given Dengzhan Shengmai(540 mg, Tid). Lipoprotein-a and C-reactive protein levels were detected respectively before and after treatment. Neurological deficit situation in patients of two groups were assessed respectively by the U.S.National Institutes of Health Stroke Scale(NIHSS score) before and after treatment,and stroke recurrence situation within 6 months of two groups were observed respectively. RESULTS: After treatment,the change of lipoprotein-a and C-reactive protein levels were different from that of before treatment, the differences were both statistically significant(P<0.01) and so did NIHSS score (P<0.05).Before treatment, lipoprotein-a and C-reactive protein levels and NIHSS score showed no-statistical significance(P>0.05);after treatment, lipoprotein-a and C-reactive protein levels and NIHSS score in observation group and control groups, the difference was significant (P<0.05). CONCLUSION: Dengzhan Shengmai capsules for secondary prevention of cerebral infarction, not only can reduce the levels of lipoprotein -a and C-reactive protein levels, but also help to improve neurological function in patients with cerebral infarction and reduce the recurrence of stroke and play an important role in secondary prevention of cerebral infarction.

Key words: Dengzhan Shengmai capsules, cerebral infarction, lipoprotein-a, C-reactive protein